By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


GlobeImmune, Inc. 

1450 Infinite Drive

Louisville  Colorado  80027  U.S.A.
Phone: 303-625-2700 Fax: 303-625-2710


Company News
Struggling GlobeImmune (GBIM) Slashing Majority of Workforce Following Failed HBV Trial 6/10/2015 6:21:29 AM
GlobeImmune, Inc. (GBIM) Announces Top Line Results From GS-4774 Phase II Trial In Virally-Suppressed Chronic HBV Patients 5/27/2015 6:10:00 AM
Gilead (GILD), GlobeImmune (GBIM)'s Hep B Drug Flunks Phase II Study 5/27/2015 6:09:10 AM
GlobeImmune, Inc. (GBIM) Announces First Quarter 2015 Results And Corporate Highlights 5/14/2015 12:19:32 PM
GlobeImmune, Inc. (GBIM) Announces Opening Of Randomized Phase 2 Chordoma Trial At National Cancer Institute 4/22/2015 10:42:17 AM
GlobeImmune, Inc. (GBIM) Announces Program Updates And Financial Results For Full Year 2014 3/17/2015 10:40:43 AM
GlobeImmune, Inc. (GBIM) To Present At The 27th Annual ROTH Conference 3/2/2015 11:16:45 AM
GlobeImmune, Inc. (GBIM) To Present At The 17th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference 2/3/2015 12:17:01 PM
GlobeImmune, Inc. (GBIM) Announces Third Quarter 2014 Financial Results 11/12/2014 2:11:56 PM
GlobeImmune, Inc. (GBIM) Release: Updated Chordoma Data From Phase 1 Study Of GI-6301 Presented At 2014 Connective Tissue Oncology Society (CTOS) Annual Meeting 10/17/2014 9:28:39 AM